StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Inflectra / Remsima (infliximab biosimilar) by Quarter

Inflectra / Remsima (infliximab biosimilar) — Worldwide operational (constant-currency) YoY (%) (%)

QuarterlyAnnual

Pfizer Inflectra / Remsima (infliximab biosimilar): 23.0% in Q2 2026, down 20.0 pts from a year earlier.

Latest, Q2 2026
23.0%
Period ended Jun 28, 2026
Change on a year earlier
-20.0 pts
43.0% in Q2 2025
History
32 quarters
Since Q1 2018
Sources
32
Documents cited below

Where the Q2 2026 figure comes from

“|| Inflectra | 171 | 139 | 23% | 23% | 165 | 100 | 66% | 5 | 39 | (86%) | (87%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedInflectra / Remsima (infliximab biosimilar) — Worldwide operational (constant-currency) YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 202623.0%-20.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202619.0%+21.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202542.0%+34.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202537.0%+32.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202543.0%+11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 2025-2.0%+10.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 20248.0%+19.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 20245.0%+13.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 202432.0%+77.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-12.0%-47.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 2023-11.0%+9.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 2023-8.0%+13.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 2023-45.0%-49.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202335.0%+58.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 2022-20.0%-11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 2022-21.0%-25.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗

Cite this data

StockData. (2026). Pfizer Inflectra / Remsima (infliximab biosimilar) (%), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/inflectra-oper-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.